Gandeeva Therapeutics develops precision medicines by integrating artificial intelligence with cryogenic electron microscopy in drug discovery. The platform identifies optimal protein interfaces to target, enabling the creation of superior small molecules and engineered antibodies. This approach focuses on developing highly targeted therapeutics, including proximity-inducing glues, for challenging diseases.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LBFounders
Product
Problem
Developing effective therapeutics for cancers and other diseases is often hindered by the difficulty in targeting and modulating protein-protein interactions (PPIs), which are critical for many biological processes. Traditional drug discovery methods struggle to identify and validate suitable targets and optimize lead compounds that can selectively disrupt or enhance these interactions. This can lead to high failure rates in late-stage clinical trials.
Solution
Gandeeva Therapeutics is developing precision medicines by targeting and modulating key protein-protein interactions (PPIs) through an integrated platform that combines cryogenic electron microscopy (cryo-EM) and machine learning. The platform enables the identification and validation of novel PPI targets, the screening of virtual and fragment libraries for hit identification, and lead optimization through structure-guided drug design. This approach facilitates the development of differentiated therapeutics, including interfacial glues (iGlues™) and allosteric inhibitors, with improved selectivity and efficacy.
Target Audience
Gandeeva's primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for cancer and other diseases with unmet medical needs, as well as patients who could benefit from more effective and targeted treatments.
Features
- SPOTLIGHT™: Target prediction and validation using cryo-EM and machine learning to identify druggable protein-protein interactions.
- HYPERFOCUS™: Hit identification by screening virtual and fragment libraries, leveraging structural data from cryo-EM.
- CRYO-CADD™: Lead optimization through structure-guided drug design, enhancing the selectivity and efficacy of therapeutic candidates.
- Development of novel protein interaction modulators, such as interfacial glues (iGlues™) and allosteric inhibitors.
- Focus on oncology, targeting difficult-to-treat cancers with innovative therapeutic modalities.
- AI-enabled platform to accelerate drug discovery and reduce the risk of clinical failures.